Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
SANDOZ INC. v. COCHRAN et al
Case Number:
1:21-cv-00600
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
Government Agencies
-
October 12, 2022
Sandoz Fights FDA Exclusivity For Sanofi MS Drug At DC Circ.
Novartis unit Sandoz is continuing its fight against the U.S. Food and Drug Administration's decision to give exclusivity to a Sanofi multiple sclerosis drug, saying at the D.C. Circuit that the agency's decision was "legally unsupportable."
-
July 22, 2022
Sandoz Loses Challenge To FDA Exclusivity For Sanofi Drug
A Washington, D.C., federal judge has ruled against Novartis unit Sandoz in its suit claiming the U.S. Food and Drug Administration improperly gave exclusivity to a Sanofi multiple sclerosis drug, finding the FDA never approved a main component of the drug as an active ingredient before it did so in the MS product.
-
March 08, 2021
Sandoz Fights FDA Exclusivity For Sanofi Blockbuster
Novartis unit Sandoz has accused the U.S. Food and Drug Administration of improperly giving exclusivity to a Sanofi multiple sclerosis drug even though its active ingredient was present in an earlier drug.